peptide administration and usage
Tirzepatide Dosage Chart: Complete Dosing Guide 2026
May
Tirzepatide Dosage Chart: Complete Dosing Guide and Escalation Schedule (2026)
Tirzepatide is one of the most clinically significant peptide compounds of the decade — a dual GIP and GLP-1 receptor agonist that has demonstrated average body weight reductions of 20 to 22 percent in clinical trials, making it the most effective approved weight management compound currently available. Whether you are researching tirzepatide dosage for clinical context, reviewing the FDA-approved tirzepatide dosage schedule, or working with research-grade tirzepatide in a laboratory setting — having a clear, accurate tirzepatide dosage chart is an essential reference tool.
This tirzepatide dosage chart guide covers the complete clinical dosage escalation schedule, the research-grade tirzepatide dosage protocol, how tirzepatide dosage relates to reconstitution volumes when working with lyophilized research compounds, the tirzepatide dosage adjustments required for different research applications, and the most important tirzepatide dosage considerations for researchers and clinicians reviewing the available evidence.
Important compliance note: TitanForge Peptides tirzepatide is supplied as a research-grade compound for in vitro laboratory use only. The tirzepatide dosage information in this chart guide is provided for research reference and informational purposes. It does not constitute medical advice and should not be interpreted as guidance for human self-administration. For pharmaceutical tirzepatide dosage guidance, consult a qualified healthcare professional.
Tirzepatide Dosage Chart: The Clinical Escalation Schedule
The tirzepatide dosage chart below reflects the FDA-approved escalation schedule used in the SURMOUNT and SURPASS clinical trial programmes — the most extensively studied tirzepatide dosage protocols in the literature. As documented in PubMed’s tirzepatide clinical trial research, the tirzepatide dosage escalation approach was developed to minimise gastrointestinal side effects — the most common adverse events associated with GLP-1 class compounds — by gradually increasing the tirzepatide dosage over a structured multi-week ramp-up period.
Tirzepatide Dosage Chart — Standard Clinical Escalation
| Tirzepatide Dosage Phase | Tirzepatide Dose | Duration | Primary Purpose |
|---|---|---|---|
| Phase 1 — Initiation | 2.5 mg weekly | Weeks 1 to 4 | Tolerability establishment — lowest tirzepatide dosage to assess individual GI response |
| Phase 2 — Escalation 1 | 5 mg weekly | Weeks 5 to 8 | First therapeutic tirzepatide dosage — meaningful GLP-1 and GIP receptor activation |
| Phase 3 — Escalation 2 | 7.5 mg weekly | Weeks 9 to 12 | Increased tirzepatide dosage for enhanced metabolic response |
| Phase 4 — Escalation 3 | 10 mg weekly | Weeks 13 to 16 | Mid-range tirzepatide dosage — strong efficacy in most trial participants |
| Phase 5 — Escalation 4 | 12.5 mg weekly | Weeks 17 to 20 | Advanced tirzepatide dosage for individuals requiring further escalation |
| Phase 6 — Maximum Dose | 15 mg weekly | Week 21 onwards | Maximum approved tirzepatide dosage — highest efficacy in SURMOUNT trials |
Key tirzepatide dosage chart notes:
- The 2.5 mg tirzepatide starting dosage is the mandatory initiation dose — beginning at a higher tirzepatide dosage significantly increases gastrointestinal side effect risk
- Each tirzepatide dosage escalation step occurs at 4-week intervals minimum — never escalate tirzepatide dosage before completing 4 weeks at the current level
- Not all individuals require escalation to the maximum 15 mg tirzepatide dosage — many achieve their target outcomes at 5 mg, 7.5 mg, or 10 mg weekly tirzepatide dosage
- The tirzepatide dosage escalation schedule can be paused at any step if gastrointestinal tolerance is insufficient — remain at the current tirzepatide dosage until tolerance improves before escalating
Tirzepatide Dosage Chart: Available Dose Strengths
The tirzepatide dosage chart below summarises all available clinical dose strengths of tirzepatide — both for pharmaceutical reference and for research-grade dosage calculation purposes:
| Tirzepatide Dosage Strength | Clinical Formulation (Mounjaro/Zepbound) | Research Grade Equivalent |
|---|---|---|
| 2.5 mg tirzepatide | Pre-filled injection pen | Reconstituted from lyophilized vial |
| 5 mg tirzepatide | Pre-filled injection pen | Reconstituted from lyophilized vial |
| 7.5 mg tirzepatide | Pre-filled injection pen | Reconstituted from lyophilized vial |
| 10 mg tirzepatide | Pre-filled injection pen | Reconstituted from lyophilized vial |
| 12.5 mg tirzepatide | Pre-filled injection pen | Reconstituted from lyophilized vial |
| 15 mg tirzepatide | Pre-filled injection pen — maximum approved tirzepatide dosage | Reconstituted from lyophilized vial |
Research-grade tirzepatide from TitanForge Peptides is supplied as a lyophilized powder in 5mg and 10mg vials — requiring reconstitution with bacteriostatic water before use. Full reconstitution instructions are available in our dedicated tirzepatide bac water mixing guide.
Tirzepatide Dosage Chart: Reconstitution Volume Calculator
When working with research-grade tirzepatide lyophilized powder, the tirzepatide dosage you draw depends on the concentration of your reconstituted solution — which in turn depends on how much bacteriostatic water you added during reconstitution. This tirzepatide dosage chart covers the most commonly used reconstitution ratios and the corresponding dose volumes:
Tirzepatide Dosage Chart — 5mg Vial Reconstitution
| Bac Water Added | Tirzepatide Concentration | 2.5 mg Dose Volume | 5 mg Dose Volume | 7.5 mg Dose Volume | 10 mg Dose Volume |
|---|---|---|---|---|---|
| 1 ml bac water | 5,000 mcg per ml | 0.5 ml | 1.0 ml | 1.5 ml | 2.0 ml |
| 2 ml bac water | 2,500 mcg per ml | 1.0 ml | 2.0 ml | 3.0 ml | 4.0 ml |
Tirzepatide Dosage Chart — 10mg Vial Reconstitution
| Bac Water Added | Tirzepatide Concentration | 2.5 mg Dose Volume | 5 mg Dose Volume | 7.5 mg Dose Volume | 10 mg Dose Volume |
|---|---|---|---|---|---|
| 1 ml bac water | 10,000 mcg per ml | 0.25 ml | 0.5 ml | 0.75 ml | 1.0 ml |
| 2 ml bac water | 5,000 mcg per ml | 0.5 ml | 1.0 ml | 1.5 ml | 2.0 ml |
| 4 ml bac water | 2,500 mcg per ml | 1.0 ml | 2.0 ml | 3.0 ml | 4.0 ml |
The recommended reconstitution ratio for most tirzepatide dosage protocols is 2 ml bac water per 5 mg tirzepatide vial — producing a 2,500 mcg per ml concentration where tirzepatide dosage volumes are practical to measure accurately with a standard insulin syringe.
Tirzepatide Dosage Chart: Insulin Syringe Units Reference
When drawing tirzepatide dosage from a reconstituted vial using a standard 1 ml insulin syringe marked in 100 units — this tirzepatide dosage chart converts ml volumes to insulin syringe units for practical reference:
Tirzepatide Dosage Chart — Syringe Units (using 2,500 mcg/ml concentration)
| Tirzepatide Dosage | Volume in ml | Insulin Syringe Units (U-100) |
|---|---|---|
| 1.25 mg tirzepatide | 0.5 ml | 50 units |
| 2.5 mg tirzepatide | 1.0 ml | 100 units |
| 5 mg tirzepatide | 2.0 ml | 200 units (2 syringes) |
Tirzepatide Dosage Chart — Syringe Units (using 5,000 mcg/ml concentration)
| Tirzepatide Dosage | Volume in ml | Insulin Syringe Units (U-100) |
|---|---|---|
| 1.25 mg tirzepatide | 0.25 ml | 25 units |
| 2.5 mg tirzepatide | 0.5 ml | 50 units |
| 5 mg tirzepatide | 1.0 ml | 100 units |
| 7.5 mg tirzepatide | 1.5 ml | 150 units (1.5 syringes) |
| 10 mg tirzepatide | 2.0 ml | 200 units (2 syringes) |
The 5,000 mcg per ml concentration — achieved by adding 2 ml bac water to a 10 mg tirzepatide vial — provides the most practical tirzepatide dosage volumes for the full clinical escalation range using a standard 1 ml insulin syringe.
Tirzepatide Dosage Chart: Efficacy Data by Dose
Understanding what the clinical evidence shows at each tirzepatide dosage level helps contextualise the significance of the escalation schedule. The following tirzepatide dosage efficacy data is drawn from the SURMOUNT-1 trial — the pivotal Phase 3 study that established tirzepatide’s clinical weight management profile, published in the New England Journal of Medicine:
| Tirzepatide Dosage | Average Weight Reduction | Participants Achieving ≥5% Weight Loss | Participants Achieving ≥15% Weight Loss |
|---|---|---|---|
| 5 mg tirzepatide weekly | ~15% of body weight | ~85% | ~40% |
| 10 mg tirzepatide weekly | ~19.5% of body weight | ~89% | ~55% |
| 15 mg tirzepatide weekly | ~20.9% of body weight | ~91% | ~57% |
| Placebo | ~3.1% of body weight | ~35% | ~3% |
This tirzepatide dosage efficacy chart demonstrates a clear dose-response relationship — higher tirzepatide dosage produces greater average weight reduction, with the 15 mg tirzepatide maximum dosage achieving the strongest efficacy outcomes in the trial. However the tirzepatide dosage chart also shows meaningful efficacy at 5 mg — indicating that escalation to maximum tirzepatide dosage is not necessary for all individuals to achieve clinically meaningful outcomes.
Tirzepatide Dosage Chart: Comparison With Semaglutide Dosing
Researchers and clinicians frequently compare tirzepatide dosage against semaglutide dosage — the GLP-1 agonist predecessor against which tirzepatide demonstrated superior efficacy in head-to-head SURPASS trials. This tirzepatide vs semaglutide dosage chart provides a direct comparison:
| Factor | Tirzepatide Dosage | Semaglutide Dosage |
|---|---|---|
| Starting dose | 2.5 mg weekly | 0.25 mg weekly |
| Maintenance doses | 5 mg, 7.5 mg, 10 mg weekly | 0.5 mg, 1 mg weekly |
| Maximum approved dose | 15 mg weekly | 2.4 mg weekly (Wegovy) |
| Dose escalation interval | 4 weeks per step | 4 weeks per step |
| Administration frequency | Once weekly | Once weekly |
| Receptor targets | GLP-1R + GIPR (dual agonist) | GLP-1R only (single agonist) |
| Peak clinical weight loss | ~20.9% body weight | ~14.9% body weight |
| Administration route | Subcutaneous injection | Subcutaneous injection |
The significantly higher tirzepatide dosage numbers compared to semaglutide reflect the different molecular potency profiles of the two compounds rather than a greater therapeutic burden — tirzepatide requires higher mg doses to achieve its clinical effects because its molecular weight and receptor binding kinetics differ from semaglutide’s. The clinical outcomes data — particularly the superior weight loss at peak tirzepatide dosage versus semaglutide — confirms that the higher tirzepatide dosage numbers translate to genuinely superior efficacy rather than simply higher drug load. Research on the comparative efficacy of tirzepatide and semaglutide is extensively covered in PubMed’s comparative GLP-1 agonist studies.
Tirzepatide Dosage Chart: Side Effect Profile by Dose
The tirzepatide dosage chart below summarises the most commonly reported adverse events by tirzepatide dosage level — drawn from SURMOUNT-1 trial data:
| Tirzepatide Dosage | Nausea Incidence | Vomiting Incidence | Diarrhoea Incidence | Discontinuation Rate |
|---|---|---|---|---|
| 5 mg tirzepatide | ~17% | ~6% | ~14% | ~4% |
| 10 mg tirzepatide | ~22% | ~9% | ~17% | ~7% |
| 15 mg tirzepatide | ~24% | ~9% | ~18% | ~9% |
| Placebo | ~10% | ~4% | ~9% | ~3% |
This tirzepatide dosage side effect chart confirms that gastrointestinal adverse events increase with tirzepatide dosage — reinforcing the clinical rationale for the gradual 4-week escalation schedule. The majority of tirzepatide dosage-related GI events are mild to moderate and transient — most resolving as the body adapts to each new tirzepatide dosage level within the first 2 weeks of escalation. As reviewed by Rupa Health’s GLP-1 agonist clinical overview, the tirzepatide dosage escalation approach is specifically designed to minimise these transient GI effects while still reaching therapeutic tirzepatide dosage levels efficiently.
Tirzepatide Dosage Chart: Research Protocol Reference
For researchers working with research-grade tirzepatide from TitanForge Peptides, the following tirzepatide dosage chart provides a reference framework for in vitro and preclinical research dosage contexts:
| Research Application | Tirzepatide Dosage Range | Notes |
|---|---|---|
| GLP-1R/GIPR binding affinity studies | Nanomolar concentrations | In vitro receptor binding |
| Metabolic pathway investigation | 0.1 nmol/kg to 1 nmol/kg | Rodent model reference |
| Insulin secretion research | Concentration-dependent | Dose-response curves |
| Comparative GLP-1 class studies | Equimolar to semaglutide | Adjust for molecular weight differences |
| Adipose tissue investigation | Variable — protocol specific | Consult published methodology |
Research-grade tirzepatide from TitanForge Peptides is independently verified to minimum 99% purity by HPLC and Mass Spectrometry, with a full batch-specific Certificate of Analysis available on our Lab Results page — providing the documentation standard required for rigorous research protocol design and publication.
Important Tirzepatide Dosage Considerations
Before using this tirzepatide dosage chart as a reference, the following tirzepatide dosage considerations are important for both clinical and research contexts:
Individual response variability — The tirzepatide dosage chart represents population-level clinical averages. Individual responses to tirzepatide dosage vary significantly based on body weight, metabolic status, concurrent medications, and GI tolerance. The tirzepatide dosage escalation schedule should always be personalised based on individual response rather than followed rigidly in isolation from clinical assessment.
Drug interactions — Tirzepatide dosage can affect the absorption of oral medications due to gastric emptying delays. Any concurrent oral medication dosage may require review when beginning or escalating tirzepatide dosage — always under appropriate medical supervision.
Contraindications — Certain medical conditions — including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and serious hypersensitivity reactions — represent absolute contraindications to tirzepatide dosage at any level. The tirzepatide dosage chart is not applicable in these circumstances.
Research use only — TitanForge Peptides tirzepatide is a research-grade compound for in vitro laboratory use only. This tirzepatide dosage chart is provided for informational and research reference purposes. All pharmaceutical tirzepatide dosage decisions must be made under the supervision of a qualified healthcare professional.
Frequently Asked Questions
Q: What is the starting tirzepatide dosage? A: The standard starting tirzepatide dosage is 2.5 mg administered subcutaneously once weekly for the first 4 weeks. This initiation tirzepatide dosage is the lowest in the escalation chart and is designed to establish GI tolerability before progressing to higher tirzepatide dosage levels. Never begin tirzepatide at a higher dosage than 2.5 mg weekly.
Q: What is the maximum tirzepatide dosage? A: The maximum FDA-approved tirzepatide dosage is 15 mg administered subcutaneously once weekly — reached after completing the full six-phase escalation schedule over approximately 20 weeks. Not all individuals require escalation to maximum tirzepatide dosage — meaningful clinical outcomes are observed across the full tirzepatide dosage range from 5 mg upwards.
Q: How often is tirzepatide dosage administered? A: Tirzepatide dosage is administered once weekly subcutaneously — on the same day each week for consistency. Unlike shorter-acting GLP-1 compounds, tirzepatide’s pharmacokinetic profile supports once-weekly tirzepatide dosage administration due to its extended half-life of approximately 5 days.
Q: How long does tirzepatide dosage escalation take? A: The complete tirzepatide dosage escalation from 2.5 mg initiation to 15 mg maximum dose takes a minimum of 20 weeks — with 4 weeks spent at each tirzepatide dosage level. The escalation schedule can be extended beyond 4 weeks at any tirzepatide dosage level if GI tolerability requires additional adaptation time.
Q: What happens if a tirzepatide dosage is missed? A: If a weekly tirzepatide dosage is missed by 4 days or less, administer the tirzepatide dosage as soon as possible and then resume the regular weekly schedule. If more than 4 days have passed since the missed tirzepatide dosage, skip it and resume the regular weekly tirzepatide dosage on the next scheduled day. Never double a tirzepatide dosage to compensate for a missed administration.
Q: How does tirzepatide dosage compare to semaglutide dosage? A: Tirzepatide dosage numbers are significantly higher than semaglutide dosage in mg terms — with tirzepatide starting at 2.5 mg weekly versus semaglutide at 0.25 mg weekly, and tirzepatide reaching a maximum of 15 mg versus semaglutide’s 2.4 mg. This reflects different molecular potency profiles rather than greater drug burden — and tirzepatide’s higher dosage range is associated with superior clinical weight loss outcomes versus semaglutide at comparable timeframes.
Q: Where can I find research-grade tirzepatide with dosage documentation? A: TitanForge Peptides supplies research-grade tirzepatide at independently verified 99%+ purity with a full batch-specific Certificate of Analysis. Shop tirzepatide research grade here.
